Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness

被引:395
作者
Golding, JF [1 ]
机构
[1] Univ Westminster, Dept Psychol, London W1R 8AL, England
基金
英国惠康基金;
关键词
emesis; motion sickness; migraine; chemotherapy; vestibular;
D O I
10.1016/S0361-9230(98)00091-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The Reason and Brand Motion Sickness Susceptibility Questionnaire (MSSQ) has remained unchanged for a quarter of a century. The primary aims of this investigation were to improve the design of the MSSQ, simplify scoring, produce new adult reference norms, and analyse motion validity data. We also considered the relationship of sickness from other nonmotion causes to the MSSQ. Norms and percentiles for a sample of 148 subjects were almost identical to the original version of this instrument. Reliability of the whole scale gave a Cronbach's standardised item alpha of 0.86, the correlation between Part A (child) and Part B (adult) was r = 0.65 (p < 0.001), end test-retest reliability may be assumed to be better than 0.8. Predictive validity of the MSSQ for motion sickness tolerance using laboratory motion devices averaged r = 0.45. Correlation between MSSQ and other sources of nausea and vomiting in the last 12 months, excluding motion sickness itself, was r = 0.3 (p < 0.001), migraine was the most important contributor to this relationship. In patients (n = 101) undergoing chemotherapy, there were significant correlations between MSSQ and chemotherapy-induced nausea and vomiting. Migraine also appeared as a predictor of chemotherapy-induced sickness. It was concluded that the revised MSSQ can be used as a direct replacement of the original version. The relationship between motion sickness susceptibility and other causes of sickness, including migraine and chemotherapy, points to the involvement of the vestibular system in the response to nonmotion emetogenic stimuli. Alternatively, this relationship may reflect individual differences in excitability of the postulated final common emetic pathway. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:507 / 516
页数:10
相关论文
共 22 条
  • [1] Baloh RW, 1998, CURR OPIN NEUROL, V11, P1
  • [2] *BRIT MED ASS ROYA, 1995, BRIT NAT FORM
  • [3] Golding J.F., 1989, 389 INM
  • [4] Golding J.F., 1993, P UK INF GROUP M HUM
  • [5] GOLDING JF, 1995, AVIAT SPACE ENVIR MD, V66, P625
  • [6] Golding JF, 1997, AVIAT SPACE ENVIR MD, V68, P396
  • [7] GOLDING JF, 1995, AVIAT SPACE ENVIR MD, V66, P1046
  • [8] Golding JF, 1996, AVIAT SPACE ENVIR MD, V67, P121
  • [9] GOLDING JF, 1992, AVIAT SPACE ENVIR MD, V63, P491
  • [10] GOLDING JF, 1996, UNPUB Y VERSUS X AXI